Company Description
Mobia Medical is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments.
Our Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the first and only clinically-validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.
Clinical data has demonstrated that Vivistim Therapy delivers meaningful improvements in upper limb function, which can help stroke survivors regain critical capabilities and independence and restore quality of life, regardless of the time elapsed since the patient’s stroke.
We believe we are setting a new standard of care in chronic stroke recovery, facilitating a new treatment pathway for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.
We have experienced rapid growth since our full commercial launch in 2023, and physicians have performed over 1,000 implants, including approximately 700 in 2025.
| Country | United States |
| Founded | 2007 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Richard Foust |
Contact Details
Address: 2802 Flintrock Trace, Suite 226 Austin, TX 78738 United States | |
| Phone | (855) 628-9375 |
| Website | mobia.com |
Stock Details
| Ticker Symbol | MOBI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1489993 |
| Employer ID | 20-8573833 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Richard Foust | President, Chief Executive Officer and Director |
| Nelson Bunker Curnes | Chief Financial Officer and Director |
| Douglas (Doug) Ellison | Chief Commercial Officer |
| Prashant Rawat | Chief Operating Officer |
| Thomas Jordan Curnes II | Co-Founder and Director |
| Chase Leavitt | General Counsel and Corporate Secretary |
| Dana G. Mead, Jr. | Chair of the Board |
| Casey Tansey | Director |
| William (Bill) Harrington | Director |
| Cynthia Lucchese | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 24, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 11, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 21, 2026 | DRS | [Cover] Draft Registration Statement |
| Mar 14, 2025 | D | Notice of Exempt Offering of Securities |
| Sep 21, 2022 | D/A | Filing |
| Jun 21, 2022 | D | Notice of Exempt Offering of Securities |
| Aug 2, 2021 | D | Notice of Exempt Offering of Securities |
| Sep 9, 2020 | D | Notice of Exempt Offering of Securities |
| Nov 21, 2017 | D | Notice of Exempt Offering of Securities |